Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosimetry-based vs Standard Lu-177-DOTATOC in NEN
NCT04917484Phase 2Recruiting
- Start
- Feb 2020
- Primary completion
- Dec 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177-edotreotide in neuroendocrine neoplasms (NENs). Started Feb 2020; status: recruiting.
02
Drugs
lutetium Lu 177-edotreotide
03
Conditions
neuroendocrine neoplasms (NENs)
Beyond the preview
Go deeper on NCT04917484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917484.